GLP-1 Weight-Loss Drugs and Male Fertility

Can GLP-1 Weight-Loss Drugs Improve Male Fertility?

Researchers reported that liraglutide and semaglutide were associated with improvements in selected male reproductive markers, including testosterone-related hormones and semen measures, while dulaglutide did not show the same clear signal. The findings are best viewed as hypothesis-generating rather than practice-changing, because fertility outcomes such as natural conception or live birth require larger, carefully controlled studies.

The medical significance comes from the overlap between obesity, insulin resistance and reproductive hormone disruption. GLP-1 receptor agonists are already used for type 2 diabetes and chronic weight management, and their broader metabolic effects may help restore a healthier endocrine environment in some men.

Why Would Obesity Treatment Affect Sperm Quality?

Excess adipose tissue can increase aromatase activity, which converts testosterone to estrogen, and is also linked with lower sex hormone-binding globulin and impaired hypothalamic-pituitary-gonadal signaling. These changes may contribute to lower testosterone, reduced sperm concentration, poorer motility or abnormal sperm morphology.

GLP-1 medicines do not act like classic fertility drugs. Their plausible benefit is indirect: lower body weight, improved insulin sensitivity, better glycemic control and reduced inflammatory stress may all support reproductive physiology. That distinction matters because a signal in semen parameters does not automatically mean a drug should be prescribed to achieve pregnancy.

Should Men Use Semaglutide or Liraglutide for Fertility?

For men with obesity, prediabetes or type 2 diabetes, GLP-1 therapy may be part of evidence-based metabolic care, but infertility still requires a standard evaluation. A semen analysis, reproductive hormone testing, medication review and assessment for varicocele, sleep apnea or other treatable causes may identify problems that weight loss alone will not fix.

Clinicians also need to avoid replacing one fertility risk with another. Testosterone replacement therapy can suppress sperm production in men who are trying to conceive, while GLP-1 medicines can cause gastrointestinal adverse effects and may not be suitable for every patient. Couples planning pregnancy should coordinate treatment timing with reproductive and metabolic specialists, especially because GLP-1 medicines are not recommended during pregnancy for the person carrying the pregnancy.